We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+18.8%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.68B
AUM Growth
+$421M
Cap. Flow
+$302M
Cap. Flow %
11.29%
Top 10 Hldgs %
68.02%
Holding
83
New
12
Increased
16
Reduced
6
Closed
11

Top Buys

1
ALEC icon
Alector
ALEC
+$68.6M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$52.4M
3
RLAY icon
Relay Therapeutics
RLAY
+$34.9M
4
RCUS icon
Arcus Biosciences
RCUS
+$32.5M
5
JANX icon
Janux Therapeutics
JANX
+$31.4M

Top Sells

1
ELDN icon
Eledon Pharmaceuticals
ELDN
+$11.9M
2
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$10.5M
3
NGNE icon
Neurogene
NGNE
+$8.45M
4
ACIU icon
AC Immune
ACIU
+$6.91M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$5.09M

Sector Composition

1 Healthcare 98.93%
2 Financials 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OVID icon
26
Ovid Therapeutics
OVID
$455M
$23.8M 0.89%
6,082,200
– –
NGNE icon
27
Neurogene
NGNE
$744M
$21.8M 0.81%
117,940
-38,195
-24% -$8.45M
ACIU icon
28
AC Immune
ACIU
$224M
$21M 0.78%
2,648,163
-1,000,000
-27% -$6.91M
BCEL
29
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$20.7M 0.77%
2,426,685
– –
CNTA
30
DELISTED
Centessa Pharmaceuticals
CNTA
$16.8M 0.63%
+754,545
New +$17.7M
KDNY
31
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$13.2M 0.49%
931,650
-318,351
-25% -$5.09M
ZNTL icon
32
Zentalis Pharmaceuticals
ZNTL
$364M
$10.6M 0.4%
+200,000
New +$10.7M
CRVS icon
33
Corvus Pharmaceuticals
CRVS
$1.25B
$9.56M 0.36%
+3,579,377
New +$9.85M
KRON
34
DELISTED
Kronos Bio
KRON
$9.28M 0.35%
387,357
– –
TNGX icon
35
Tango Therapeutics
TNGX
$4.65B
$9.1M 0.34%
800,000
– –
NUVB.WS
36
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$8.97M 0.34%
963,333
– –
KLRS
37
Kalaris Therapeutics
KLRS
$104M
$8.82M 0.33%
19,435
– –
CCCC icon
38
C4 Therapeutics
CCCC
$408M
$7.57M 0.28%
200,000
– –
CYCN icon
39
Cyclerion Therapeutics
CYCN
$15.8M
$6.26M 0.23%
80,314
– –
VERV
40
DELISTED
Verve Therapeutics
VERV
$6.03M 0.23%
+100,000
New +$4.15M
SYRS
41
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.45M 0.2%
100,000
– –
JYAC
42
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.97M 0.19%
500,000
– –
ALPN
43
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.7M 0.18%
522,635
-218,655
-29% -$2.38M
DYN icon
44
Dyne Therapeutics
DYN
$3.92B
$4.52M 0.17%
215,000
– –
OBIO icon
45
Orchestra BioMed
OBIO
$220M
$4.08M 0.15%
400,000
– –
DNTH icon
46
Dianthus Therapeutics
DNTH
$5.77B
$3.59M 0.13%
22,929
-11,843
-34% -$2.18M
IGMS
47
DELISTED
IGM Biosciences
IGMS
$3.16M 0.12%
+38,030
New +$2.82M
ODT
48
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$2.9M 0.11%
+831,200
New +$2.85M
NGM
49
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$2.83M 0.11%
143,567
– –
FMTX
50
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$2.63M 0.1%
+105,638
New +$2.84M
1
2
3 4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q2 2021 Portfolio in Review

As of Q2 2021, EcoR1 Capital held 83 positions worth $2.68B, up 19% from $2.25B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital deployed $302M of net new capital in Q2 2021, opening 12 new positions and adding to 16 existing holdings. Its largest new stake was Janux Therapeutics: 1,411,975 shares worth $35.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Neurogene, an estimated $8.45M trimmed.

  • EcoR1 Capital's largest Q2 2021 buy was Janux Therapeutics: 1,411,975 shares worth $35.2M.
  • EcoR1 Capital added most to Alector in Q2 2021, an estimated $68.6M increase.
  • EcoR1 Capital's biggest Q2 2021 reduction was Neurogene, cutting an estimated $8.45M.
  • EcoR1 Capital fully exited Eledon Pharmaceuticals in Q2 2021, selling an estimated $11.9M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $2.68B portfolio in Q2 2021.
  • EcoR1 Capital opened 12 new positions and closed 11 in Q2 2021.
  • EcoR1 Capital's portfolio value rose 19% quarter-over-quarter to $2.68B.

Based on EcoR1 Capital's 13F filing for Q2 2021, filed 16 Aug 2021.